CD4 and cancer: An upregulation of HLA-DRA expression is associated with antitumour immune response, whereby it functions in presenting tumour-associated antigens (TAA) on cancer cells that trigger CD4+ Th1 cells and NK cells, with the production of IFN-γ, an antitumour cytokine.